SAMSUNG-ELECTRONICS
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced the ISOCELL HP1, the industry’s first 200-megapixel (MP) image sensor with 0.64μm pixels, and ISOCELL GN5, the first image sensor to adopt all-directional focusing Dual Pixel Pro technology with two photodiodes in a single 1.0μm pixel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005321/en/
“Samsung has been pioneering ultrafine pixel technologies that are taking high-resolution image sensors to the next level,” said Duckhyun Chang, executive vice president of sensor business at Samsung Electronics. “With the ISOCELL HP1 that is breaking barriers and ISOCELL GN5 bringing ultrafast auto focus, Samsung will continue to lead the trend for next-generation mobile imaging technologies.”
ISOCELL HP1: Capture the world in breathtaking 200MP and crystal sharp 8K video
The ISOCELL HP1 is the industry’s first mobile image sensor to support 200MP. Based on Samsung’s most advanced 0.64μm-sized pixels, the ISOCELL HP1 brings such ultrahigh resolution in a small package that fits comfortably in today’s handheld devices. With the ISOCELL HP1, pictures hold an astonishing amount of detail that helps the image stay sharp even when cropped or resized.
For ultimate low-light photography, the ISOCELL HP1 features an all-new ChameleonCell technology, a pixel-binning technology that uses a two-by-two, four-by-four or full pixel layout depending on the environment. In a low-lit environment, the HP1 transforms into a 12.5MP image sensor with large 2.56μm pixels by merging 16 neighboring pixels. The newly formed 2.56μm pixel is capable of more light absorption and sensitivity, producing brighter and clearer photos in in-doors or in the evening. In bright outdoor environments, the sensor’s 200-million pixels can capture ultra-high-definition photography on mobile devices.
The ISOCELL HP1 can take 8K videos at 30 frames-per-second (fps) with minimum loss in the field of view. The HP1 merges four neighboring pixels to bring the resolution down to 50MP or 8,192 x 6,144 to take 8K (7,680 x 4,320) videos without the need to crop or scale down the full image resolution.
ISOCELL GN5: Lock on instantly and take super-sharp hi-res images with all-directional autofocus
The ISOCELL GN5 is the industry’s first 1.0μm image sensor to integrate Dual Pixel Pro, an all-directional autofocusing technology, that can substantially boost autofocusing capabilities. This technology places two photodiodes, the smallest in the industry, within each 1.0μm pixel of the sensor either horizontally or vertically to recognize pattern changes in all directions. With one million phase-detecting multi-directional photodiodes covering all areas of the sensor, the ISOCELL GN5’s autofocusing becomes instantaneous, enabling sharper images in either bright or low-lit environments.
The image sensor also makes use of Samsung’s proprietary pixel technology, which applies Front Deep Trench Isolation (FDTI) on a Dual Pixel product for the first time in the industry. Despite the microscopic photodiode size, FDTI enables each photodiode to absorb and hold more light information, improving the photodiodes’ full-well capacity (FWC) and decreasing crosstalk within the pixel.
Samples of Samsung ISOCELL HP1 and GN5 are currently available.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and ISOCELL 2.0 technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005321/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom